KHEDEZLA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KHEDEZLA (KHEDEZLA).
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that selectively inhibits the reuptake of serotonin and norepinephrine, thereby enhancing neurotransmission in the central nervous system.
| Metabolism | Primarily metabolized by conjugation (glucuronidation) and to a minor extent by CYP3A4. The major metabolite is desvenlafaxine glucuronide. |
| Excretion | Primarily renal (70-80% as unchanged desvenlafaxine), with minor fecal elimination (approx. 5%). |
| Half-life | Approximately 11 hours; supports once-daily dosing; steady state reached within 3 days. |
| Protein binding | 30% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | 3.4 L/kg; indicates extensive extravascular distribution consistent with moderate lipophilicity. |
| Bioavailability | Approximately 80% after oral administration; not affected by food. |
| Onset of Action | Therapeutic effects may be observed within 1-2 weeks, with full antidepressant response typically requiring 4-8 weeks of continuous dosing. |
| Duration of Action | 24 hours with once-daily administration; sustained symptom relief between doses due to half-life. |
20 mg orally once daily, with or without food.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may be more sensitive to adverse effects. Use caution, and initiate at lower dose if clinically indicated. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KHEDEZLA (KHEDEZLA).
| Breastfeeding | Desvenlafaxine is excreted into breast milk; relative infant dose approximately 5–7% (M/P ratio not well established). Monitor infant for drowsiness and milk intake. Benefit of treating maternal depression should outweigh potential risks. |
| Teratogenic Risk | KHEDEZLA (desvenlafaxine) is an SNRI. First trimester: Limited human data; no consistent evidence of major congenital malformations but cannot exclude risk. Second and third trimester: Risk of serotonin reuptake inhibitor syndrome in neonates, including respiratory distress, feeding difficulty, and agitation; also associated with persistent pulmonary hypertension of the newborn (PPHN). |
■ FDA Black Box Warning
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
["Concomitant use with MAOIs or within 14 days of discontinuing an MAOI","Concomitant use with linezolid or intravenous methylene blue"]
| Precautions | ["Suicidality","Serotonin syndrome","Elevated blood pressure","Increased risk of bleeding","Activation of mania/hypomania","Angle-closure glaucoma","Discontinuation syndrome","Seizures","Hyponatremia","Use with MAOIs"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, mood, and serotonin syndrome symptoms. Fetal ultrasound for growth and well-being. Newborn monitoring for symptoms of serotonin discontinuation syndrome and PPHN. |
| Fertility Effects | KHEDEZLA may cause hyperprolactinemia and galactorrhea, potentially affecting fertility. In animal studies, no significant adverse effects on fertility were observed; human data limited. |